Cargando…

Early detection of colorectal cancer somatic mutations using cfDNA liquid biopsies in a murine carcinogenesis model

Colorectal cancer (CRC) is one of the top five cancers in incidence and mortality worldwide. The early detection of this neoplasm through analysis of circulating free DNA (cfDNA), which carries tumor genetic alterations, as a liquid biopsy, could have a major impact in enhancing early detection and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Gregorio, Héctor, Díaz-Velásquez, Clara Estela, Romero-Piña, Mario Esaú, Ruiz De La Cruz, Miguel, Delgado-Buenrostro, Norma Laura, De La Cruz-Montoya, Aldo, Chirino, Yolanda Irasema, Terrazas, Luis Ignacio, Medina, Luis Alberto, Vaca-Paniagua, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608204/ https://www.ncbi.nlm.nih.gov/pubmed/36313038 http://dx.doi.org/10.7150/jca.76516

Ejemplares similares

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

Cis-Acting Factors Causing Secondary Epimutations: Impact on the Risk for Cancer and Other Diseases
por: Ruiz de la Cruz, Miguel, et al.
Publicado: (2021)

Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM
por: Albitar, A, et al.
Publicado: (2018)

CfDNA Measurement as a Diagnostic Tool for the Detection of Brain Somatic Mutations in Refractory Epilepsy
por: Mayo, Sonia, et al.
Publicado: (2022)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients
por: Boldrin, Elisa, et al.
Publicado: (2020)

Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020)

cfDNA Changes in Maximal Exercises as a Sport Adaptation Predictor
por: Humińska-Lisowska, Kinga, et al.
Publicado: (2021)

Deep cfDNA fragment end profiling enables cancer detection
por: Zhitnyuk, Yulia V., et al.
Publicado: (2022)

Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
por: Sugasawa, Takehito, et al.
Publicado: (2021)

The utility of cfDNA in TGCT patient management: a systematic review
por: Krasic, Jure, et al.
Publicado: (2022)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
por: Liang, Leilei, et al.
Publicado: (2022)

cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps
por: Li, Xiao-Hong, et al.
Publicado: (2022)

Hypertensive disorders of pregnancy share common cfDNA methylation profiles
por: Spinelli, Marialuigia, et al.
Publicado: (2022)

Brave new world of cfDNA-omics for early cancer detection
por: Rolfo, Christian, et al.
Publicado: (2023)

Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic
por: Rojas-Jiménez, Ernesto, et al.
Publicado: (2020)

The Evolution of Clinically Aggressive Triple-Negative Breast Cancer Shows a Large Mutational Diversity and Early Metastasis to Lymph Nodes
por: Martínez-Gregorio, Héctor, et al.
Publicado: (2021)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
por: McEwen, Abbye E., et al.
Publicado: (2020)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data
por: Han, Xinyin, et al.
Publicado: (2021)

Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
por: Barbirou, Mouadh, et al.
Publicado: (2022)

Erratum to “The utility of cfDNA in TGCT patient management: a systematic review”
Publicado: (2022)

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker
por: Škara, Lucija, et al.
Publicado: (2023)

cfDNA methylome profiling for detection and subtyping of small cell lung cancers
por: Chemi, Francesca, et al.
Publicado: (2022)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
por: Pokrywka, Andrzej, et al.
Publicado: (2015)

Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nb63td105vj66gaiil3539pftr